Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I. Sherman

Showing results (91-100 of 141) with videos related to

Pageof 15
Sort By:
Thyroid : Official Journal of the American Thyroid Association|March 13, 2014
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutationsThereasa A Rich, Lei Feng, Naifa Busaidy, et al.
Head & Neck|January 24, 2008
Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern eraDavid L Schwartz, Vishal Rana, Stephanie Shaw, et al.
JCO Precision Oncology|September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated MalignanciesVivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2014
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenibRamona Dadu, Catherine Devine, Mike Hernandez, et al.
Cancer|October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialMarcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
The Lancet. Oncology|July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialMarcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
JCO Oncology Practice|December 19, 2025
Increasing Access and Quality Care for Immune Checkpoint Inhibitor-Related Thyroid DysfunctionAnne K Brinkman, Amori Y Salami-Henry, Lori A Aaron-Brija, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerMartin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
Pageof 15

Showing results (91-100 of 141) with videos related to

Sort By:
Pageof 15
Thyroid : Official Journal of the American Thyroid Association|March 13, 2014
Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutationsThereasa A Rich, Lei Feng, Naifa Busaidy, et al.
Head & Neck|January 24, 2008
Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern eraDavid L Schwartz, Vishal Rana, Stephanie Shaw, et al.
JCO Precision Oncology|September 11, 2020
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i>-Mutated MalignanciesVivek Subbiah, Shiraj Sen, Kenneth R Hess, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2014
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenibRamona Dadu, Catherine Devine, Mike Hernandez, et al.
Cancer|October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trialMarcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
The Lancet. Oncology|July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialMarcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
JCO Oncology Practice|December 19, 2025
Increasing Access and Quality Care for Immune Checkpoint Inhibitor-Related Thyroid DysfunctionAnne K Brinkman, Amori Y Salami-Henry, Lori A Aaron-Brija, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancerMartin J Schlumberger, Rossella Elisei, Lars Bastholt, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
Pageof 15